Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Ophthalmological
- Pharmaceuticals
- Nutraceutical
- Medical
- Device
- Diagnostic
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2709
License Grant
The Licensee entered into an exclusive License Agreement with two individuals pursuant to which the Licensee Licensed the rights for the manufacture, distribution and marketing of products based on Z-monocys – zinc-based moiety, zinc-monocysteine. -monocys is initially being developed as an oral treatment for dry age-related macular degeneration (AMD).
License Property
Z-monocys is a patented composition of matter protected by U.S. patent 6,586,611, issued Jul. 1, 2003, and U.S. patent 7,164,035, issued Jan. 16, 2007. Macular degeneration is a progressive eye condition affecting approximately 10 million Americans. AMD is associated with tissue deterioration in the center of vision, the macula of the retina, where the sharpest vision occurs in the eye.
Zinc, an essential nutrient, is the second most abundant trace element in the human body and the most abundant trace element in the eye. It is necessary for the activity of more than 200 enzymes and for the DNA binding capacity of over 400 nuclear regulatory elements. There is evidence that zinc may function as an antioxidant by protecting sulfhydryl groups from oxidation, competing with copper and iron to reduce the formation of hydroxyl radicals which are a result of redox cycling and by the induction of the antioxidant protein metallothionein (MT) which can scavenge damaging hydroxyls.
Field of Use
Field of Use shall mean all human and animal uses.
IPSCIO Record ID: 344589
License Grant
Licensor grants an exclusive, worldwide license and sublicense, with the right to sublicense, under the Licensor Technology, based on existing agreements in place, to research, develop, use, have used, make, have made, import or have imported, export or have exported, offer for sale or have offered for sale, and/or sell or have sold Licensed Products in the Field.
License Property
The various patents relate to Treating Ocular Disorders and include but are not limited to
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved · for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
Field of Use
Licensee has the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).
AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.
Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.
IPSCIO Record ID: 7490
License Grant
The Japanese Licensee will acquire rights to the Licensor's lead candidate, ACU-4429, and potential backup compounds in Japan and certain other Asian countries and will collaborate with the Licensor on the further development and commercialization of Collaboration Products in the Shared territory.
License Property
ACU-4429 is the Licensor's small-molecule visual cycle modulator (VCM) being developed to treat dry age-related macular degeneration (dry AMD), which occurs when light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
Field of Use
Field means the diagnosis, treatment, palliation and/or prevention of ophthalmologic conditions, maladies and diseases, including age-related macular degeneration and diabetic retinopathy.
IPSCIO Record ID: 1039
License Grant
A federal jury found the Company liable for certain inventions relating to the use of verteporfin (the active pharmaceutical ingredient in Visudyne®) as the photoactive agent in the treatment of certain eye diseases including AMD – a treatment for the wet form of Age related macular degeneration.
IPSCIO Record ID: 297723
License Grant
Pursuant to the License Agreement, the Licensor has granted an exclusive license to the Hong Kong Licensee to develop, distribute, promote, market and commercialize XIPERE, subject to specified exceptions in the Territory.
License Property
XIPERE, is proprietary suspension of the corticosteroid triamcinolone acetonide. The formulated product is for administration to the back of the eye, using the Licensor’s proprietary SCS Microinjector, the device.
Field of Use
The patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye.
The field of use is for the treatment of macular edema associated with uveitis.
Uveitis is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea). Uveitis (u-vee-I-tis) warning signs often come on suddenly and get worse quickly. They include eye redness, pain and blurred vision. The condition can affect one or both eye. Macular edema is the build-up of fluid in the macula, an area in the center of the retina.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
